Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Etropal ADXBUL:ETR 50 Receivables Turnover is 15.72 as of Dec. 2025. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.78 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Etropal AD ranks better than 95.31% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Etropal AD's Revenue for the
six
months ended in Dec. 2025 was €10.44 Mil. Etropal AD's average Accounts Receivable for the
six
months ended in Dec. 2025 was €0.66 Mil.
Hence, Etropal AD's Receivables Turnover for the
six
months ended in Dec. 2025 was 15.72.
Etropal AD (XBUL:ETR) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Etropal AD Receivables Turnover Related Terms
Etropal AD Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Etropal AD's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, MDLN: Receivables Turnover Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Etropal AD's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Etropal AD (XBUL:ETR) has a Receivables Turnover of 15.72 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #38 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 4.7%.
Is Etropal AD's Receivables Turnover too high?
Etropal AD's current Receivables Turnover is 15.72. The Medical Devices & Instruments industry median Receivables Turnover is 5.61. Etropal AD's value of 15.72 is 180.2% above this industry median. Based on the distribution chart, Etropal AD ranks #38 out of 811 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's Receivables Turnover compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #38 out of 811 companies for Receivables Turnover. This places Etropal AD in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.61. Etropal AD's value of 15.72 is 180.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.61, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current Receivables Turnover of 15.72 is 180.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current Receivables Turnover is 15.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.78, compared to a current price of €2.66 — trading 69.7% below its estimated fair value. The current Receivables Turnover is 15.72 and 180.2% above the Medical Devices & Instruments industry median of 5.61. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current Receivables Turnover is 15.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.66 is trading 69.7% below its estimated GF Value™ of €8.78.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
Receivables Turnover: 15.72
GF Value™: €8.78 vs. price of €2.66 (69.7% below fair value)
Industry Position: 180.2% above the Medical Devices & Instruments median (#38 of 811)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
